Teva Used Priority Voucher for Migraine Drug
Federal Register notice: FDA has announced an approval for Teva’s Ajovy (fremanezumab-vfrm) injection for preventing migraine in adults under a redeemed priority review voucher. Such vouchers are awarded to sponsors of approved rare pediatric disease product applications that meet certain criteria. The agency is required to publish notice of the issuance of vouchers as well as the approval of products redeeming a voucher. To view the notice, click here.